オピオイド拮抗薬のグローバル市場インサイト・予測（～2027年）

• 英文タイトル：Global Opioid Antagonist Market Insights and Forecast to 2027

• レポートコード：QY2112C03899 • 出版社/出版日：QYResearch / 2021年12月 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、107ページ • 納品方法：Eメール（納期：3日） • 産業分類：医薬品

• 販売価格（消費税別）

Single User	￥735,000 (USD4,900)	▷ お問い合わせ
Multi User	￥1,102,500 (USD7,350)	▷ お問い合わせ
Enterprise License	￥1,470,000 (USD9,800)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

本調査資料はオピオイド拮抗薬の世界市場の現状について調査・分析し、2027年までの市場を予測しました。オピオイド拮抗薬の世界市場概要、メーカー別の競争状況と市場シェア、種類別市場規模（経口、非経口）、用途別市場規模（病院、クリニック、その他）、主要地域別市場規模（北米・アメリカ、ヨーロッパ、アジア・日本・中国・インド、中南米、中東・アフリカ）、関連企業の情報、バリューチェーン・販売チャネル、市場動向などを収録しています。 ・オピオイド拮抗薬の世界市場概要 ・メーカー別の競争状況、市場シェア ・オピオイド拮抗薬の種類別市場規模：経口、非経口 ・オピオイド拮抗薬の用途別市場規模：病院、クリニック、その他 ・北米のオピオイド拮抗薬市場規模2016-2027：種類別、用途別、国別（アメリカ、カナダ） ・ヨーロッパのオピオイド拮抗薬市場規模2016-2027：種類別、用途別、国別（ドイツ、フランス、イギリス） ・アジアのオピオイド拮抗薬市場規模2016-2027：種類別、用途別、国別（日本、中国、インド、韓国） ・中南米のオピオイド拮抗薬市場規模2016-2027：種類別、用途別、国別（メキシコ、ブラジル） ・中東・アフリカのオピオイド拮抗薬市場規模2016-2027：種類別、用途別、国別（トルコ、サウジアラビア） ・企業情報：Indivior、Alkermes、Titan Pharmaceuticals、Opiant Pharmaceuticals、Hikma Pharmaceuticals、Orexo、Camurus、Acura Pharmaceuticals、Shionogi、BioDelivery Sciences International、Collegium Pharmaceutical、AstraZeneca ・オピオイド拮抗薬のバリューチェーン・販売チャネル分析 ・オピオイド拮抗薬の世界市場動向

Market Analysis and Insights: Global Opioid Antagonist Market
The global Opioid Antagonist market is valued at US$ million in 2020. The market size will reach US$ million by the end of 2027, growing at a CAGR of % during 2021-2027.

Global Opioid Antagonist Scope and Segment
Opioid Antagonist market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Opioid Antagonist market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2016-2027.

Segment by Type
Oral
Parenteral

Segment by Application
Hospitals
Clinics
Others

By Company
Indivior
Alkermes
Titan Pharmaceuticals
Opiant Pharmaceuticals
Hikma Pharmaceuticals
Orexo
Camurus
Acura Pharmaceuticals
Shionogi
BioDelivery Sciences International
Collegium Pharmaceutical
AstraZeneca

By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

レポート目次

---

1 Study Coverage
1.1 Opioid Antagonist Product Introduction
1.2 Market by Type
1.2.1 Global Opioid Antagonist Market Size Growth Rate by Type
1.2.2 Oral
1.2.3 Parenteral
1.3 Market by Application
1.3.1 Global Opioid Antagonist Market Size Growth Rate by Application
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered

2 Executive Summary
2.1 Global Opioid Antagonist Sales Estimates and Forecasts 2016-2027
2.2 Global Opioid Antagonist Revenue Estimates and Forecasts 2016-2027
2.3 Global Opioid Antagonist Revenue by Region: 2016 VS 2021 VS 2027
2.4 Global Top Opioid Antagonist Regions by Sales
2.4.1 Global Top Opioid Antagonist Regions by Sales (2016-2021)
2.4.2 Global Top Opioid Antagonist Regions by Sales (2022-2027)
2.5 Global Top Opioid Antagonist Regions by Revenue
2.5.1 Global Top Opioid Antagonist Regions by Revenue (2016-2021)
2.5.2 Global Top Opioid Antagonist Regions by Revenue (2022-2027)
2.6 North America
2.7 Europe
2.8 Asia-Pacific
2.9 Latin America
2.10 Middle East & Africa

3 Competition by Manufacturers
3.1 Global Opioid Antagonist Sales by Manufacturers
3.1.1 Global Top Opioid Antagonist Manufacturers by Sales (2016-2021)
3.1.2 Global Top Opioid Antagonist Manufacturers Market Share by Sales (2016-2021)
3.1.3 Global Top 10 and Top 5 Companies by Opioid Antagonist Sales in 2020
3.2 Global Opioid Antagonist Revenue by Manufacturers
3.2.1 Global Top Opioid Antagonist Manufacturers by Revenue (2016-2021)
3.2.2 Global Top Opioid Antagonist Manufacturers Market Share by Revenue (2016-2021)
3.2.3 Global Top 10 and Top 5 Companies by Opioid Antagonist Revenue in 2020
3.3 Global Opioid Antagonist Sales Price by Manufacturers
3.4 Analysis of Competitive Landscape
3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Opioid Antagonist Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4.3 Global Opioid Antagonist Manufacturers Geographical Distribution
3.5 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type
4.1 Global Opioid Antagonist Sales by Type
4.1.1 Global Opioid Antagonist Historical Sales by Type (2016-2021)
4.1.2 Global Opioid Antagonist Forecasted Sales by Type (2022-2027)
4.1.3 Global Opioid Antagonist Sales Market Share by Type (2016-2027)
4.2 Global Opioid Antagonist Revenue by Type
4.2.1 Global Opioid Antagonist Historical Revenue by Type (2016-2021)
4.2.2 Global Opioid Antagonist Forecasted Revenue by Type (2022-2027)
4.2.3 Global Opioid Antagonist Revenue Market Share by Type (2016-2027)
4.3 Global Opioid Antagonist Price by Type
4.3.1 Global Opioid Antagonist Price by Type (2016-2021)
4.3.2 Global Opioid Antagonist Price Forecast by Type (2022-2027)

5 Market Size by Application
5.1 Global Opioid Antagonist Sales by Application
5.1.1 Global Opioid Antagonist Historical Sales by Application (2016-2021)
5.1.2 Global Opioid Antagonist Forecasted Sales by Application (2022-2027)
5.1.3 Global Opioid Antagonist Sales Market Share by Application (2016-2027)
5.2 Global Opioid Antagonist Revenue by Application
5.2.1 Global Opioid Antagonist Historical Revenue by Application (2016-2021)
5.2.2 Global Opioid Antagonist Forecasted Revenue by Application (2022-2027)
5.2.3 Global Opioid Antagonist Revenue Market Share by Application (2016-2027)
5.3 Global Opioid Antagonist Price by Application
5.3.1 Global Opioid Antagonist Price by Application (2016-2021)
5.3.2 Global Opioid Antagonist Price Forecast by Application (2022-2027)

6 North America
6.1 North America Opioid Antagonist Market Size by Type
6.1.1 North America Opioid Antagonist Sales by Type (2016-2027)
6.1.2 North America Opioid Antagonist Revenue by Type (2016-2027)
6.2 North America Opioid Antagonist Market Size by Application
6.2.1 North America Opioid Antagonist Sales by Application (2016-2027)
6.2.2 North America Opioid Antagonist Revenue by Application (2016-2027)
6.3 North America Opioid Antagonist Market Size by Country
6.3.1 North America Opioid Antagonist Sales by Country (2016-2027)
6.3.2 North America Opioid Antagonist Revenue by Country (2016-2027)
6.3.3 United States
6.3.4 Canada

7 Europe
7.1 Europe Opioid Antagonist Market Size by Type
7.1.1 Europe Opioid Antagonist Sales by Type (2016-2027)
7.1.2 Europe Opioid Antagonist Revenue by Type (2016-2027)
7.2 Europe Opioid Antagonist Market Size by Application
7.2.1 Europe Opioid Antagonist Sales by Application (2016-2027)
7.2.2 Europe Opioid Antagonist Revenue by Application (2016-2027)
7.3 Europe Opioid Antagonist Market Size by Country
7.3.1 Europe Opioid Antagonist Sales by Country (2016-2027)
7.3.2 Europe Opioid Antagonist Revenue by Country (2016-2027)
7.3.3 Germany
7.3.4 France
7.3.5 U.K.
7.3.6 Italy
7.3.7 Russia

8 Asia Pacific
8.1 Asia Pacific Opioid Antagonist Market Size by Type
8.1.1 Asia Pacific Opioid Antagonist Sales by Type (2016-2027)
8.1.2 Asia Pacific Opioid Antagonist Revenue by Type (2016-2027)
8.2 Asia Pacific Opioid Antagonist Market Size by Application
8.2.1 Asia Pacific Opioid Antagonist Sales by Application (2016-2027)
8.2.2 Asia Pacific Opioid Antagonist Revenue by Application (2016-2027)
8.3 Asia Pacific Opioid Antagonist Market Size by Region
8.3.1 Asia Pacific Opioid Antagonist Sales by Region (2016-2027)
8.3.2 Asia Pacific Opioid Antagonist Revenue by Region (2016-2027)
8.3.3 China
8.3.4 Japan
8.3.5 South Korea
8.3.6 India
8.3.7 Australia
8.3.8 China Taiwan
8.3.9 Indonesia
8.3.10 Thailand
8.3.11 Malaysia

9 Latin America
9.1 Latin America Opioid Antagonist Market Size by Type
9.1.1 Latin America Opioid Antagonist Sales by Type (2016-2027)
9.1.2 Latin America Opioid Antagonist Revenue by Type (2016-2027)
9.2 Latin America Opioid Antagonist Market Size by Application
9.2.1 Latin America Opioid Antagonist Sales by Application (2016-2027)
9.2.2 Latin America Opioid Antagonist Revenue by Application (2016-2027)
9.3 Latin America Opioid Antagonist Market Size by Country
9.3.1 Latin America Opioid Antagonist Sales by Country (2016-2027)
9.3.2 Latin America Opioid Antagonist Revenue by Country (2016-2027)
9.3.3 Mexico
9.3.4 Brazil
9.3.5 Argentina

10 Middle East and Africa
10.1 Middle East and Africa Opioid Antagonist Market Size by Type
10.1.1 Middle East and Africa Opioid Antagonist Sales by Type (2016-2027)
10.1.2 Middle East and Africa Opioid Antagonist Revenue by Type (2016-2027)
10.2 Middle East and Africa Opioid Antagonist Market Size by Application
10.2.1 Middle East and Africa Opioid Antagonist Sales by Application (2016-2027)
10.2.2 Middle East and Africa Opioid Antagonist Revenue by Application (2016-2027)
10.3 Middle East and Africa Opioid Antagonist Market Size by Country
10.3.1 Middle East and Africa Opioid Antagonist Sales by Country (2016-2027)
10.3.2 Middle East and Africa Opioid Antagonist Revenue by Country (2016-2027)
10.3.3 Turkey
10.3.4 Saudi Arabia

11 Company Profiles
11.1 Indivior
11.1.1 Indivior Corporation Information
11.1.2 Indivior Overview
11.1.3 Indivior Opioid Antagonist Sales, Price, Revenue and Gross Margin (2016-2021)
11.1.4 Indivior Opioid Antagonist Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 Indivior Recent Developments
11.2 Alkermes
11.2.1 Alkermes Corporation Information
11.2.2 Alkermes Overview
11.2.3 Alkermes Opioid Antagonist Sales, Price, Revenue and Gross Margin (2016-2021)
11.2.4 Alkermes Opioid Antagonist Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 Alkermes Recent Developments
11.3 Titan Pharmaceuticals
11.3.1 Titan Pharmaceuticals Corporation Information
11.3.2 Titan Pharmaceuticals Overview
11.3.3 Titan Pharmaceuticals Opioid Antagonist Sales, Price, Revenue and Gross Margin (2016-2021)
11.3.4 Titan Pharmaceuticals Opioid Antagonist Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 Titan Pharmaceuticals Recent Developments
11.4 Opiant Pharmaceuticals
11.4.1 Opiant Pharmaceuticals Corporation Information
11.4.2 Opiant Pharmaceuticals Overview
11.4.3 Opiant Pharmaceuticals Opioid Antagonist Sales, Price, Revenue and Gross Margin (2016-2021)
11.4.4 Opiant Pharmaceuticals Opioid Antagonist Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Opiant Pharmaceuticals Recent Developments
11.5 Hikma Pharmaceuticals
11.5.1 Hikma Pharmaceuticals Corporation Information
11.5.2 Hikma Pharmaceuticals Overview
11.5.3 Hikma Pharmaceuticals Opioid Antagonist Sales, Price, Revenue and Gross Margin (2016-2021)
11.5.4 Hikma Pharmaceuticals Opioid Antagonist Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 Hikma Pharmaceuticals Recent Developments
11.6 Orexo
11.6.1 Orexo Corporation Information
11.6.2 Orexo Overview
11.6.3 Orexo Opioid Antagonist Sales, Price, Revenue and Gross Margin (2016-2021)
11.6.4 Orexo Opioid Antagonist Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 Orexo Recent Developments
11.7 Camurus
11.7.1 Camurus Corporation Information
11.7.2 Camurus Overview
11.7.3 Camurus Opioid Antagonist Sales, Price, Revenue and Gross Margin (2016-2021)
11.7.4 Camurus Opioid Antagonist Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 Camurus Recent Developments
11.8 Acura Pharmaceuticals
11.8.1 Acura Pharmaceuticals Corporation Information
11.8.2 Acura Pharmaceuticals Overview
11.8.3 Acura Pharmaceuticals Opioid Antagonist Sales, Price, Revenue and Gross Margin (2016-2021)
11.8.4 Acura Pharmaceuticals Opioid Antagonist Product Model Numbers, Pictures, Descriptions and Specifications
11.8.5 Acura Pharmaceuticals Recent Developments
11.9 Shionogi
11.9.1 Shionogi Corporation Information
11.9.2 Shionogi Overview
11.9.3 Shionogi Opioid Antagonist Sales, Price, Revenue and Gross Margin (2016-2021)
11.9.4 Shionogi Opioid Antagonist Product Model Numbers, Pictures, Descriptions and Specifications
11.9.5 Shionogi Recent Developments
11.10 BioDelivery Sciences International
11.10.1 BioDelivery Sciences International Corporation Information
11.10.2 BioDelivery Sciences International Overview
11.10.3 BioDelivery Sciences International Opioid Antagonist Sales, Price, Revenue and Gross Margin (2016-2021)
11.10.4 BioDelivery Sciences International Opioid Antagonist Product Model Numbers, Pictures, Descriptions and Specifications
11.10.5 BioDelivery Sciences International Recent Developments
11.11 Collegium Pharmaceutical
11.11.1 Collegium Pharmaceutical Corporation Information
11.11.2 Collegium Pharmaceutical Overview
11.11.3 Collegium Pharmaceutical Opioid Antagonist Sales, Price, Revenue and Gross Margin (2016-2021)
11.11.4 Collegium Pharmaceutical Opioid Antagonist Product Model Numbers, Pictures, Descriptions and Specifications
11.11.5 Collegium Pharmaceutical Recent Developments
11.12 AstraZeneca
11.12.1 AstraZeneca Corporation Information
11.12.2 AstraZeneca Overview
11.12.3 AstraZeneca Opioid Antagonist Sales, Price, Revenue and Gross Margin (2016-2021)
11.12.4 AstraZeneca Opioid Antagonist Product Model Numbers, Pictures, Descriptions and Specifications
11.12.5 AstraZeneca Recent Developments

12 Value Chain and Sales Channels Analysis
12.1 Opioid Antagonist Value Chain Analysis
12.2 Opioid Antagonist Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Opioid Antagonist Production Mode & Process
12.4 Opioid Antagonist Sales and Marketing
12.4.1 Opioid Antagonist Sales Channels
12.4.2 Opioid Antagonist Distributors
12.5 Opioid Antagonist Customers

13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis
13.1 Opioid Antagonist Industry Trends
13.2 Opioid Antagonist Market Drivers
13.3 Opioid Antagonist Market Challenges
13.4 Opioid Antagonist Market Restraints

14 Key Findings in The Global Opioid Antagonist Study

15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

List of Tables
Table 1. Global Opioid Antagonist Market Size Growth Rate by Type, 2016 VS 2021 VS 2027 (US$ Million)
Table 2. Major Manufacturers of Oral
Table 3. Major Manufacturers of Parenteral
Table 4. Global Opioid Antagonist Market Size Growth Rate by Application, 2016 VS 2021 VS 2027 (US$ Million)
Table 5. Global Opioid Antagonist Revenue by Region: 2016 VS 2021 VS 2027 (US$ Million)
Table 6. Global Opioid Antagonist Sales by Region (2016-2021) & (K Units)
Table 7. Global Opioid Antagonist Sales Market Share by Region (2016-2021)
Table 8. Global Opioid Antagonist Sales by Region (2022-2027) & (K Units)
Table 9. Global Opioid Antagonist Sales Market Share by Region (2022-2027)
Table 10. Global Opioid Antagonist Revenue by Region (2016-2021) & (US$ Million)
Table 11. Global Opioid Antagonist Revenue Market Share by Region (2016-2021)
Table 12. Global Opioid Antagonist Revenue by Region (2022-2027) & (US$ Million)
Table 13. Global Opioid Antagonist Revenue Market Share by Region (2022-2027)
Table 14. Global Opioid Antagonist Sales by Manufacturers (2016-2021) & (K Units)
Table 15. Global Opioid Antagonist Sales Share by Manufacturers (2016-2021)
Table 16. Global Opioid Antagonist Revenue by Manufacturers (2016-2021) & (US$ Million)
Table 17. Global Opioid Antagonist Revenue Share by Manufacturers (2016-2021)
Table 18. Opioid Antagonist Price by Manufacturers 2016-2021 (US$/Unit)
Table 19. Global Opioid Antagonist Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 20. Global Opioid Antagonist by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Opioid Antagonist as of 2020)
Table 21. Opioid Antagonist Manufacturing Base Distribution and Headquarters
Table 22. Manufacturers Opioid Antagonist Product Offered
Table 23. Date of Manufacturers Enter into Opioid Antagonist Market
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Opioid Antagonist Sales by Type (2016-2021) & (K Units)
Table 26. Global Opioid Antagonist Sales by Type (2022-2027) & (K Units)
Table 27. Global Opioid Antagonist Sales Share by Type (2016-2021)
Table 28. Global Opioid Antagonist Sales Share by Type (2022-2027)
Table 29. Global Opioid Antagonist Revenue by Type (2016-2021) & (US$ Million)
Table 30. Global Opioid Antagonist Revenue by Type (2022-2027) & (US$ Million)
Table 31. Global Opioid Antagonist Revenue Share by Type (2016-2021)
Table 32. Global Opioid Antagonist Revenue Share by Type (2022-2027)
Table 33. Opioid Antagonist Price by Type (2016-2021) & (US$/Unit)
Table 34. Global Opioid Antagonist Price Forecast by Type (2022-2027) & (US$/Unit)
Table 35. Global Opioid Antagonist Sales by Application (2016-2021) & (K Units)
Table 36. Global Opioid Antagonist Sales by Application (2022-2027) & (K Units)
Table 37. Global Opioid Antagonist Sales Share by Application (2016-2021)
Table 38. Global Opioid Antagonist Sales Share by Application (2022-2027)
Table 39. Global Opioid Antagonist Revenue by Application (2016-2021) & (US$ Million)
Table 40. Global Opioid Antagonist Revenue by Application (2022-2027) & (US$ Million)
Table 41. Global Opioid Antagonist Revenue Share by Application (2016-2021)
Table 42. Global Opioid Antagonist Revenue Share by Application (2022-2027)
Table 43. Opioid Antagonist Price by Application (2016-2021) & (US$/Unit)
Table 44. Global Opioid Antagonist Price Forecast by Application (2022-2027) & (US$/Unit)
Table 45. North America Opioid Antagonist Sales by Type (2016-2021) & (K Units)
Table 46. North America Opioid Antagonist Sales by Type (2022-2027) & (K Units)
Table 47. North America Opioid Antagonist Revenue by Type (2016-2021) & (US$ Million)
Table 48. North America Opioid Antagonist Revenue by Type (2022-2027) & (US$ Million)
Table 49. North America Opioid Antagonist Sales by Application (2016-2021) & (K Units)
Table 50. North America Opioid Antagonist Sales by Application (2022-2027) & (K Units)
Table 51. North America Opioid Antagonist Revenue by Application (2016-2021) & (US$ Million)
Table 52. North America Opioid Antagonist Revenue by Application (2022-2027) & (US$ Million)
Table 53. North America Opioid Antagonist Sales by Country (2016-2021) & (K Units)
Table 54. North America Opioid Antagonist Sales by Country (2022-2027) & (K Units)
Table 55. North America Opioid Antagonist Revenue by Country (2016-2021) & (US$ Million)
Table 56. North America Opioid Antagonist Revenue by Country (2022-2027) & (US$ Million)
Table 57. Europe Opioid Antagonist Sales by Type (2016-2021) & (K Units)
Table 58. Europe Opioid Antagonist Sales by Type (2022-2027) & (K Units)
Table 59. Europe Opioid Antagonist Revenue by Type (2016-2021) & (US$ Million)
Table 60. Europe Opioid Antagonist Revenue by Type (2022-2027) & (US$ Million)
Table 61. Europe Opioid Antagonist Sales by Application (2016-2021) & (K Units)
Table 62. Europe Opioid Antagonist Sales by Application (2022-2027) & (K Units)
Table 63. Europe Opioid Antagonist Revenue by Application (2016-2021) & (US$ Million)
Table 64. Europe Opioid Antagonist Revenue by Application (2022-2027) & (US$ Million)
Table 65. Europe Opioid Antagonist Sales by Country (2016-2021) & (K Units)
Table 66. Europe Opioid Antagonist Sales by Country (2022-2027) & (K Units)
Table 67. Europe Opioid Antagonist Revenue by Country (2016-2021) & (US$ Million)
Table 68. Europe Opioid Antagonist Revenue by Country (2022-2027) & (US$ Million)
Table 69. Asia Pacific Opioid Antagonist Sales by Type (2016-2021) & (K Units)
Table 70. Asia Pacific Opioid Antagonist Sales by Type (2022-2027) & (K Units)
Table 71. Asia Pacific Opioid Antagonist Revenue by Type (2016-2021) & (US$ Million)
Table 72. Asia Pacific Opioid Antagonist Revenue by Type (2022-2027) & (US$ Million)
Table 73. Asia Pacific Opioid Antagonist Sales by Application (2016-2021) & (K Units)
Table 74. Asia Pacific Opioid Antagonist Sales by Application (2022-2027) & (K Units)
Table 75. Asia Pacific Opioid Antagonist Revenue by Application (2016-2021) & (US$ Million)
Table 76. Asia Pacific Opioid Antagonist Revenue by Application (2022-2027) & (US$ Million)
Table 77. Asia Pacific Opioid Antagonist Sales by Region (2016-2021) & (K Units)
Table 78. Asia Pacific Opioid Antagonist Sales by Region (2022-2027) & (K Units)
Table 79. Asia Pacific Opioid Antagonist Revenue by Region (2016-2021) & (US$ Million)
Table 80. Asia Pacific Opioid Antagonist Revenue by Region (2022-2027) & (US$ Million)
Table 81. Latin America Opioid Antagonist Sales by Type (2016-2021) & (K Units)
Table 82. Latin America Opioid Antagonist Sales by Type (2022-2027) & (K Units)
Table 83. Latin America Opioid Antagonist Revenue by Type (2016-2021) & (US$ Million)
Table 84. Latin America Opioid Antagonist Revenue by Type (2022-2027) & (US$ Million)
Table 85. Latin America Opioid Antagonist Sales by Application (2016-2021) & (K Units)
Table 86. Latin America Opioid Antagonist Sales by Application (2022-2027) & (K Units)
Table 87. Latin America Opioid Antagonist Revenue by Application (2016-2021) & (US$ Million)
Table 88. Latin America Opioid Antagonist Revenue by Application (2022-2027) & (US$ Million)
Table 89. Latin America Opioid Antagonist Sales by Country (2016-2021) & (K Units)
Table 90. Latin America Opioid Antagonist Sales by Country (2022-2027) & (K Units)
Table 91. Latin America Opioid Antagonist Revenue by Country (2016-2021) & (US$ Million)
Table 92. Latin America Opioid Antagonist Revenue by Country (2022-2027) & (US$ Million)
Table 93. Middle East and Africa Opioid Antagonist Sales by Type (2016-2021) & (K Units)
Table 94. Middle East and Africa Opioid Antagonist Sales by Type (2022-2027) & (K Units)
Table 95. Middle East and Africa Opioid Antagonist Revenue by Type (2016-2021) & (US$ Million)
Table 96. Middle East and Africa Opioid Antagonist Revenue by Type (2022-2027) & (US$ Million)
Table 97. Middle East and Africa Opioid Antagonist Sales by Application (2016-2021) & (K Units)
Table 98. Middle East and Africa Opioid Antagonist Sales by Application (2022-2027) & (K Units)
Table 99. Middle East and Africa Opioid Antagonist Revenue by Application (2016-2021) & (US$ Million)
Table 100. Middle East and Africa Opioid Antagonist Revenue by Application (2022-2027) & (US$ Million)
Table 101. Middle East and Africa Opioid Antagonist Sales by Country (2016-2021) & (K Units)
Table 102. Middle East and Africa Opioid Antagonist Sales by Country (2022-2027) & (K Units)
Table 103. Middle East and Africa Opioid Antagonist Revenue by Country (2016-2021) & (US$ Million)
Table 104. Middle East and Africa Opioid Antagonist Revenue by Country (2022-2027) & (US$ Million)
Table 105. Indivior Corporation Information
Table 106. Indivior Description and Major Businesses
Table 107. Indivior Opioid Antagonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2016-2021)
Table 108. Indivior Opioid Antagonist Product Model Numbers, Pictures, Descriptions and Specifications
Table 109. Indivior Recent Developments
Table 110. Alkermes Corporation Information
Table 111. Alkermes Description and Major Businesses
Table 112. Alkermes Opioid Antagonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2016-2021)
Table 113. Alkermes Opioid Antagonist Product Model Numbers, Pictures, Descriptions and Specifications
Table 114. Alkermes Recent Developments
Table 115. Titan Pharmaceuticals Corporation Information
Table 116. Titan Pharmaceuticals Description and Major Businesses
Table 117. Titan Pharmaceuticals Opioid Antagonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2016-2021)
Table 118. Titan Pharmaceuticals Opioid Antagonist Product Model Numbers, Pictures, Descriptions and Specifications
Table 119. Titan Pharmaceuticals Recent Developments
Table 120. Opiant Pharmaceuticals Corporation Information
Table 121. Opiant Pharmaceuticals Description and Major Businesses
Table 122. Opiant Pharmaceuticals Opioid Antagonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2016-2021)
Table 123. Opiant Pharmaceuticals Opioid Antagonist Product Model Numbers, Pictures, Descriptions and Specifications
Table 124. Opiant Pharmaceuticals Recent Developments
Table 125. Hikma Pharmaceuticals Corporation Information
Table 126. Hikma Pharmaceuticals Description and Major Businesses
Table 127. Hikma Pharmaceuticals Opioid Antagonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2016-2021)
Table 128. Hikma Pharmaceuticals Opioid Antagonist Product Model Numbers, Pictures, Descriptions and Specifications
Table 129. Hikma Pharmaceuticals Recent Developments
Table 130. Orexo Corporation Information
Table 131. Orexo Description and Major Businesses
Table 132. Orexo Opioid Antagonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2016-2021)
Table 133. Orexo Opioid Antagonist Product Model Numbers, Pictures, Descriptions and Specifications
Table 134. Orexo Recent Developments
Table 135. Camurus Corporation Information
Table 136. Camurus Description and Major Businesses
Table 137. Camurus Opioid Antagonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2016-2021)
Table 138. Camurus Opioid Antagonist Product Model Numbers, Pictures, Descriptions and Specifications
Table 139. Camurus Recent Developments
Table 140. Acura Pharmaceuticals Corporation Information
Table 141. Acura Pharmaceuticals Description and Major Businesses
Table 142. Acura Pharmaceuticals Opioid Antagonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2016-2021)
Table 143. Acura Pharmaceuticals Opioid Antagonist Product Model Numbers, Pictures, Descriptions and Specifications
Table 144. Acura Pharmaceuticals Recent Developments
Table 145. Shionogi Corporation Information
Table 146. Shionogi Description and Major Businesses
Table 147. Shionogi Opioid Antagonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2016-2021)
Table 148. Shionogi Opioid Antagonist Product Model Numbers, Pictures, Descriptions and Specifications
Table 149. Shionogi Recent Developments
Table 150. BioDelivery Sciences International Corporation Information
Table 151. BioDelivery Sciences International Description and Major Businesses
Table 152. BioDelivery Sciences International Opioid Antagonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2016-2021)
Table 153. BioDelivery Sciences International Opioid Antagonist Product Model Numbers, Pictures, Descriptions and Specifications
Table 154. BioDelivery Sciences International Recent Developments
Table 155. Collegium Pharmaceutical Corporation Information
Table 156. Collegium Pharmaceutical Description and Major Businesses
Table 157. Collegium Pharmaceutical Opioid Antagonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2016-2021)
Table 158. Collegium Pharmaceutical Opioid Antagonist Product Model Numbers, Pictures, Descriptions and Specifications
Table 159. Collegium Pharmaceutical Recent Developments
Table 160. AstraZeneca Corporation Information
Table 161. AstraZeneca Description and Major Businesses
Table 162. AstraZeneca Opioid Antagonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2016-2021)
Table 163. AstraZeneca Opioid Antagonist Product Model Numbers, Pictures, Descriptions and Specifications
Table 164. AstraZeneca Recent Developments
Table 165. Key Raw Materials Lists
Table 166. Raw Materials Key Suppliers Lists
Table 167. Opioid Antagonist Distributors List
Table 168. Opioid Antagonist Customers List
Table 169. Opioid Antagonist Market Trends
Table 170. Opioid Antagonist Market Drivers
Table 171. Opioid Antagonist Market Challenges
Table 172. Opioid Antagonist Market Restraints
Table 173. Research Programs/Design for This Report
Table 174. Key Data Information from Secondary Sources
Table 175. Key Data Information from Primary Sources
List of Figures
Figure 1. Opioid Antagonist Product Picture
Figure 2. Global Opioid Antagonist Market Share by Type in 2020 & 2027
Figure 3. Oral Product Picture
Figure 4. Parenteral Product Picture
Figure 5. Global Opioid Antagonist Market Share by Application in 2020 & 2027
Figure 6. Hospitals
Figure 7. Clinics
Figure 8. Others
Figure 9. Opioid Antagonist Report Years Considered
Figure 10. Global Opioid Antagonist Sales 2016-2027 (K Units)
Figure 11. Global Opioid Antagonist Revenue, (US$ Million), 2016 VS 2021 VS 2027
Figure 12. Global Opioid Antagonist Revenue 2016-2027 (US$ Million)
Figure 13. Global Opioid Antagonist Revenue Market Share by Region in Percentage: 2020 Versus 2027
Figure 14. Global Opioid Antagonist Sales Market Share by Region (2016-2021)
Figure 15. Global Opioid Antagonist Sales Market Share by Region (2022-2027)
Figure 16. North America Opioid Antagonist Sales YoY (2016-2027) & (K Units)
Figure 17. North America Opioid Antagonist Revenue YoY (2016-2027) & (US$ Million)
Figure 18. Europe Opioid Antagonist Sales YoY (2016-2027) & (K Units)
Figure 19. Europe Opioid Antagonist Revenue YoY (2016-2027) & (US$ Million)
Figure 20. Asia-Pacific Opioid Antagonist Sales YoY (2016-2027) & (K Units)
Figure 21. Asia-Pacific Opioid Antagonist Revenue YoY (2016-2027) & (US$ Million)
Figure 22. Latin America Opioid Antagonist Sales YoY (2016-2027) & (K Units)
Figure 23. Latin America Opioid Antagonist Revenue YoY (2016-2027) & (US$ Million)
Figure 24. Middle East & Africa Opioid Antagonist Sales YoY (2016-2027) & (K Units)
Figure 25. Middle East & Africa Opioid Antagonist Revenue YoY (2016-2027) & (US$ Million)
Figure 26. The Top 10 and Top 5 Players Market Share by Opioid Antagonist Sales in 2020
Figure 27. The Top 10 and Top 5 Players Market Share by Opioid Antagonist Revenue in 2020
Figure 28. Opioid Antagonist Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2016 VS 2020
Figure 29. Global Opioid Antagonist Sales Market Share by Type (2016-2027)
Figure 30. Global Opioid Antagonist Revenue Market Share by Type (2016-2027)
Figure 31. Global Opioid Antagonist Sales Market Share by Application (2016-2027)
Figure 32. Global Opioid Antagonist Revenue Market Share by Application (2016-2027)
Figure 33. North America Opioid Antagonist Sales Market Share by Type (2016-2027)
Figure 34. North America Opioid Antagonist Revenue Market Share by Type (2016-2027)
Figure 35. North America Opioid Antagonist Sales Market Share by Application (2016-2027)
Figure 36. North America Opioid Antagonist Revenue Market Share by Application (2016-2027)
Figure 37. North America Opioid Antagonist Sales Share by Country (2016-2027)
Figure 38. North America Opioid Antagonist Revenue Share by Country (2016-2027)
Figure 39. United States Opioid Antagonist Revenue (2016-2027) & (US$ Million)
Figure 40. Canada Opioid Antagonist Revenue (2016-2027) & (US$ Million)
Figure 41. Europe Opioid Antagonist Sales Market Share by Type (2016-2027)
Figure 42. Europe Opioid Antagonist Revenue Market Share by Type (2016-2027)
Figure 43. Europe Opioid Antagonist Sales Market Share by Application (2016-2027)
Figure 44. Europe Opioid Antagonist Revenue Market Share by Application (2016-2027)
Figure 45. Europe Opioid Antagonist Sales Share by Country (2016-2027)
Figure 46. Europe Opioid Antagonist Revenue Share by Country (2016-2027)
Figure 47. Germany Opioid Antagonist Revenue (2016-2027) & (US$ Million)
Figure 48. France Opioid Antagonist Revenue (2016-2027) & (US$ Million)
Figure 49. U.K. Opioid Antagonist Revenue (2016-2027) & (US$ Million)
Figure 50. Italy Opioid Antagonist Revenue (2016-2027) & (US$ Million)
Figure 51. Russia Opioid Antagonist Revenue (2016-2027) & (US$ Million)
Figure 52. Asia Pacific Opioid Antagonist Sales Market Share by Type (2016-2027)
Figure 53. Asia Pacific Opioid Antagonist Revenue Market Share by Type (2016-2027)
Figure 54. Asia Pacific Opioid Antagonist Sales Market Share by Application (2016-2027)
Figure 55. Asia Pacific Opioid Antagonist Revenue Market Share by Application (2016-2027)
Figure 56. Asia Pacific Opioid Antagonist Sales Share by Region (2016-2027)
Figure 57. Asia Pacific Opioid Antagonist Revenue Share by Region (2016-2027)
Figure 58. China Opioid Antagonist Revenue (2016-2027) & (US$ Million)
Figure 59. Japan Opioid Antagonist Revenue (2016-2027) & (US$ Million)
Figure 60. South Korea Opioid Antagonist Revenue (2016-2027) & (US$ Million)
Figure 61. India Opioid Antagonist Revenue (2016-2027) & (US$ Million)
Figure 62. Australia Opioid Antagonist Revenue (2016-2027) & (US$ Million)
Figure 63. China Taiwan Opioid Antagonist Revenue (2016-2027) & (US$ Million)
Figure 64. Indonesia Opioid Antagonist Revenue (2016-2027) & (US$ Million)
Figure 65. Thailand Opioid Antagonist Revenue (2016-2027) & (US$ Million)
Figure 66. Malaysia Opioid Antagonist Revenue (2016-2027) & (US$ Million)
Figure 67. Latin America Opioid Antagonist Sales Market Share by Type (2016-2027)
Figure 68. Latin America Opioid Antagonist Revenue Market Share by Type (2016-2027)
Figure 69. Latin America Opioid Antagonist Sales Market Share by Application (2016-2027)
Figure 70. Latin America Opioid Antagonist Revenue Market Share by Application (2016-2027)
Figure 71. Latin America Opioid Antagonist Sales Share by Country (2016-2027)
Figure 72. Latin America Opioid Antagonist Revenue Share by Country (2016-2027)
Figure 73. Mexico Opioid Antagonist Revenue (2016-2027) & (US$ Million)
Figure 74. Brazil Opioid Antagonist Revenue (2016-2027) & (US$ Million)
Figure 75. Argentina Opioid Antagonist Revenue (2016-2027) & (US$ Million)
Figure 76. Middle East and Africa Opioid Antagonist Sales Market Share by Type (2016-2027)
Figure 77. Middle East and Africa Opioid Antagonist Revenue Market Share by Type (2016-2027)
Figure 78. Middle East and Africa Opioid Antagonist Sales Market Share by Application (2016-2027)
Figure 79. Middle East and Africa Opioid Antagonist Revenue Market Share by Application (2016-2027)
Figure 80. Middle East and Africa Opioid Antagonist Sales Share by Country (2016-2027)
Figure 81. Middle East and Africa Opioid Antagonist Revenue Share by Country (2016-2027)
Figure 82. Turkey Opioid Antagonist Revenue (2016-2027) & (US$ Million)
Figure 83. Saudi Arabia Opioid Antagonist Revenue (2016-2027) & (US$ Million)
Figure 84. UAE Opioid Antagonist Revenue (2016-2027) & (US$ Million)
Figure 85. Opioid Antagonist Value Chain
Figure 86. Opioid Antagonist Production Process
Figure 87. Channels of Distribution
Figure 88. Distributors Profiles
Figure 89. Bottom-up and Top-down Approaches for This Report
Figure 90. Data Triangulation
Figure 91. Key Executives Interviewed

---